Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening

World Journal of Gastroenterology

Volumn 22, Issue 12, 2016, Pages 3460-3470

  Kuo, Ming Jeng ^a   Chen, Hsiu Hsi ^b   Chen, Chi Ling ^b,c   Fann, Jean Ching Yuan ^d   Chen, Sam Li Sheng ^e   Chiu, Sherry Yueh Hsia ^f   Lin, Yu Min ^g   Liao, Chao Sheng ^h   Chang, Hung Chuen ^g   Lin, Yueh Shih ^g   Yen, Amy Ming Fang ^e  

^a TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Department of Psychiatry   (Taiwan)

^d KAINAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^h Yangder Health Clinics   (Taiwan)

Author keywords

Age; Cost effectiveness; Markov model; One stage abdominal ultrasonography screening; Sensitivity analysis; Two stage biomarker ultrasound screening

Indexed keywords

AGE; ARTICLE; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; ECHOGRAPHY; HIDDEN MARKOV MODEL; HUMAN; LIVER CELL CARCINOMA; MASS SCREENING; SENSITIVITY ANALYSIS; TAIWAN; ADULT; AGED; BLOOD; BLOOD ANALYSIS; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECONOMIC MODEL; ECONOMICS; FEMALE; HEALTH CARE COST; LIVER NEOPLASMS; MALE; MARKOV CHAIN; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY;

BIOLOGICAL MARKER;

ADULT; AGED; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMANS; LIVER NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TAIWAN; ULTRASONOGRAPHY;

EID: 84996520549     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i12.3460     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. Cancer statistics. Taiwan Cancer Registry. Assessed 2010-05-20. Avaiable from: URL: http://crs.cph.ntu.edu.tw/main.php
3. Jan CF, Chen CJ, Chen HH. Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol 2005; 20: 521-526 [PMID: 15836699 DOI: 10.1111/j.1440-1746.2005.03602.x]
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133 [PMID: 6118576 DOI: 10.1016/S0140-6736(81)90585-7]
5. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859 [PMID: 9197213 DOI: 10.1056/nejm199706263362602]
6. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 148-155 [PMID: 17339159 DOI: 10.1016/s0929-6646(09)60231-x]
7. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108-S112 [PMID: 15508073 DOI: 10.1053/j.gastro.2004.09.023]
8. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422 [PMID: 15042359 DOI: 10.1007/s00432-004-0552-0]
9. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003; (2): CD002799 [PMID: 12804438 DOI: 10.1002/14651858.cd002799]
10. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, Lee HS, Duffy SW. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002; 98: 257-261 [PMID: 11857416 DOI: 10.1002/ijc.10122]
11. Mima S, Sekiya C, Kanagawa H, Kohyama H, Gotoh K, Mizuo H, Ijiri M, Tanabe T, Maeda N, Okuda K. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994; 9: 361-365 [PMID: 7524721 DOI: 10.1111/j.1440-1746.1994.tb01256.x]
12. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438 [PMID: 7543434 DOI: 10.1016/0270-9139(95)90562-6]
13. Chen CJ, Lu SN, You SL, Wu MH, Wang LY, Lee LT, Huang GT, Yang PM, Lee HS. [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. J Formos Med Assoc 1995; 94 Suppl 2: S94-S102 [PMID: 8672950]
14. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108-110 [PMID: 10444731 DOI: 10.1136/jms.6.2.108]
15. Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J 2004; 10: 317-325 [PMID: 15530261 DOI: 10.1097/00130404-200409000-00009]
16. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956 [PMID: 2834034 DOI: 10.1002/1097-0142(19880515)61]
17. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-241 [PMID: 2770436 DOI: 10.1111/j.1600-0676.1989.tb00405.x]
18. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472 [PMID: 9024300 DOI: 10.1053/gast.1997. v112.pm9024300]
19. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440 [PMID: 9581703 DOI: 10.1002/hep.510270535]
20. Kuo MJ, Yeh HZ, Chen GH, Poon SK, Yang SS, Lien HC, Chang CS. Improvement of tissue-adhesive obliteration of bleeding gastric varices using adjuvant hypertonic glucose injection: a prospective randomized trial. Endoscopy 2007; 39: 487-491 [PMID: 17354182 DOI: 10.1055/s-2007-966267]
21. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21: 303-308 [PMID: 8514896 DOI: 10.1002/jcu.1870210502]
22. Yang B, Zhang B, Tang Z. [Randomized controlled prospective study of secondary prevention for primary liver cancer]. Zhonghua Yi Xue Zazhi 1999; 79: 887-889 [PMID: 11715499]
23. Wu GH, Boucher BJ, Chiu YH, Liao CS, Chen TH. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutr 2009; 12: 129-135 [PMID: 18410705 DOI: 10.1017/S1368980008002073]
24. Chen TH, Chiu YH, Luh DL, Yen MF, Wu HM, Chen LS, Tung TH, Huang CC, Chan CC, Shiu MN, Yeh YP, Liou HH, Liao CS, Lai HC, Chiang CP, Peng HL, Tseng CD, Yen MS, Hsu WC, Chen CH. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004; 100: 1734-1743 [PMID: 15073864 DOI: 10.1002/cncr.20171]
25. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417-426 [PMID: 7861461 DOI: 10.1093/jnci/87.6.417]
26. Wu CL, Yang MC. Morbidity Costs and Associated Factors of Patients with Hepatocellular Carcinoma from a Medical Center. Chin J Pub Health 1998: 148-157
27. Yang SS, Tang TS, Hong WH. Medical Cost Analysis on Patients with Hepatocellular Carcinoma. Taipei: Medical Center Taipei Medical University, 2003: 67
28. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528 [PMID: 15367247 DOI: 10.1111/j.1524-4733.2004.75003.x]
29. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107: 2212-2222 [PMID: 17019738 DOI: 10.1002/cncr.22242]
30. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113-S120 [PMID: 16447288 DOI: 10.1002/hep.21046]
31. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6]
32. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259 [PMID: 11156649 DOI: 10.1136/gut.48.2.251]
33. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434 [PMID: 8873514 DOI: 10.1016/s0002-9343(96)00197-0]
34. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Chen P, Schwegel K, Goldstein LI, Tong M, Busuttil RW. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9: 672-681 [PMID: 12827551 DOI: 10.1053/jlts.2003.50120]
35. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19: 1159-1172 [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x]
36. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-690 [PMID: 12650806 DOI: 10.1111/j.1572-0241.2003.07327.x]
37. Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc 2010; 109: 39-55 [PMID: 20123585 DOI: 10.1016/S0929-6646(10)60020-4]
38. Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, Chiu SY, Fann JC, Su WW, Fang YJ, Chen ST, San HC, Chen HP, Liao CS. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology 2014; 59: 1840-1849 [PMID: 24002724 DOI: 10.1002/hep.26703]
39. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]
40. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763 [PMID: 18471552 DOI: 10.1053/j.gastro.2008.02.090]